- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 25.11. | Psyence Biomedical launches psilocybin longevity research program | 2 | Investing.com | ||
| 20.11. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 20.11. | Psyence BioMed secures sustainable iboga supply for clinical research | 1 | Investing.com | ||
| 20.11. | Psyence Biomedical Ltd.: Psyence BioMed Reaches Major Breakthrough in Pharmaceutical-Grade Ibogaine Supply for Worldwide Clinical and Therapeutic Markets | 197 | GlobeNewswire (Europe) | NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine... ► Artikel lesen | |
| 12.11. | Psyence BioMed baut mit strategischer Investition Ibogain-Produktion in Afrika auf | 3 | Investing.com Deutsch | ||
| 12.11. | Psyence BioMed establishes Africa operations for ibogaine production | 2 | Investing.com | ||
| 06.11. | Psyence BioMed advances Phase IIb psilocybin trial for palliative care | 1 | Investing.com | ||
| 03.11. | Psyence Biomedical invests $3.5 million in psychedelic API producer | 4 | Investing.com | ||
| PSYENCE BIOMEDICAL Aktie jetzt für 0€ handeln | |||||
| 03.11. | Psyence Biomedical Ltd.: Psyence BioMed Strengthens Strategic Partnership with PsyLabs Through USD $3,500,000 Follow-On Investment | 131 | GlobeNewswire (Europe) | NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and Ibogaine... ► Artikel lesen | |
| 14.10. | PSYENCE BIOMEDICAL LTD. - F-1/A, Registration statement for certain foreign private issuers | 1 | SEC Filings | ||
| 09.10. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 06.10. | PSYENCE BIOMEDICAL LTD. - F-1/A, Registration statement for certain foreign private issuers | 4 | SEC Filings | ||
| 05.09. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 28.08. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 04.08. | Psyence Biomedical Ltd.: Corporate Update, August 2025 | 325 | GlobeNewswire (Europe) | NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- From Dr. Neil Maresky, CEO, Psyence BioMed (NASDAQ: PBM) Dear Shareholders, Thank you for your continued support as we advance our mission to develop safe... ► Artikel lesen | |
| 01.08. | Pre-market Movers: Namib Minerals, 4D Molecular Therapeutics, CCC Intelligent Solutions, Enovix, Psyence Biomedical | 887 | AFX News | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 06.25 A.M. ET).In the Green Namib Minerals (NAMM) is up over 108% at $8.26.
4D... ► Artikel lesen | |
| 31.07. | Pre-market Movers: VerifyMe, Psyence Biomedical, Pineapple Financial, Align Technology, Confluent | 714 | AFX News | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.50 A.M. ET).In the Green VerifyMe, Inc. (VRME) is up over 79% at $1.23.
Psyence... ► Artikel lesen | |
| 31.07. | Psyence Biomedical stock soars after partner achieves ibogaine breakthrough | 15 | Investing.com | ||
| 31.07. | Psyence Biomedical Ltd.: Psyence BioMed's Strategic Collaboration with PsyLabs Yields Breakthrough in High-Purity Ibogaine Production | 271 | GlobeNewswire (Europe) | NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company") is pleased to announce that its strategic partner, PsyLabs - a leader in the production... ► Artikel lesen | |
| 23.07. | PSYENCE BIOMEDICAL LTD. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings |
1 2 Weiter >>
40 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOLINERX | 2,545 | -7,12 % | BioLineRx Ltd.: BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update | - Establishes joint venture with Hemispherian AS to advance GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other... ► Artikel lesen | |
| TRANSCODE THERAPEUTICS | 8,750 | -1,46 % | TransCode Therapeutics, Inc.: TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO | Safety primary endpoint achieved
Median treatment duration of 4 months with a range of 2 to 12 months and three patients remain on trial
RECIST data with... ► Artikel lesen | |
| SILEXION THERAPEUTICS | 3,020 | -3,82 % | Silexion Therapeutics Corp: Silexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic Cancer | ||
| MINK THERAPEUTICS | 10,400 | +4,00 % | MiNK Therapeutics Reports Q3 2025 Results and Accelerates iNKT Platform Toward Pivotal Development Across Oncology, Pulmonary Disease, and Transplantation | New clinical data show durable remissions and long-tail survivors including >2-year complete remissions in chemotherapy- and checkpoint-refractory cancersGVHD trial launching through non-dilutive... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 247,99 | +30,54 % | Morning Market Movers: SMX, Praxis Precision Medicines, Polyrizon, Rubrik, Inc. See Big Swings | HONG KONG (dpa-AFX) - At 7:50 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| VERA THERAPEUTICS | 44,900 | +5,37 % | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| COGENT BIOSCIENCES | 38,770 | -1,37 % | Cogent Biosciences, Inc.: Cogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 67th Annual Meeting of the American Society of Hematology (ASH) | ||
| ARCUTIS BIOTHERAPEUTICS | 31,200 | +0,13 % | Arcutis Biotherapeutics, Inc.: FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5 | Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children... ► Artikel lesen | |
| NUVALENT | 109,60 | +2,56 % | Nuvalent, Inc.: Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC | NDA based on data from global ARROS-1 Phase 1/2 clinical trial
FDA assigns PDUFA target action date of September 18, 2026
CAMBRIDGE, Mass., Nov. 19, 2025 /PRNewswire/... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 71,63 | +0,13 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| QIAGEN | 40,405 | -0,02 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| ADMA BIOLOGICS | 19,850 | -1,29 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,710 | -4,27 % | Recursion Pharmaceuticals: Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update | Achieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells-the second neuro map designed to accelerate treatments for a wide range of neurological... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 76,75 | +1,66 % | Apogee Therapeutics: Noch ein sharedealsPlus-Verdoppler! | Im Juli hatten wir mit der Aktie von Apogee Therapeutics einen Verdopplungskandidaten identifiziert. Jetzt, keine fünf Monate später, konnte die Aktie tatsächlich mehr als +100% zulegen. Ein weiterer... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 38,500 | -1,05 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | - Submission of New Drug Application (NDA) for lorundrostat planned for late-2025/Q1 2026 - - Completed enrollment in Explore-OSA trial; topline results anticipated in Q1 2026 - - Conference call... ► Artikel lesen |
PSYENCE BIOMEDICAL LTD gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -2,21 % bei einem Aktienkurs von 1,770 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PSYENCE BIOMEDICAL LTD finden Sie auf Wallstreet Online.